Publication: 2297

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study
      QxMD      Google Scholar   
Citation:
Br J Haematol vol 171 (3) 373-377
Year:
2015
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
5
Parents:
816  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, CA33601, CA77597, CA04457, CA101140, CA77406, CA47577, CA29165, U10 CA045564, CA41287, U10 CA045808, CA03927, U10 CA031946, U10 CA033601, CA59518, U10 CA180821, CA26806, U10 CA077597, CA45808, U10 CA059518, U10 CA045418, U10CA180882, U10 CA077440, CA16450, U10 CA101140, CA77440, U10 CA041287, CA45564, U10 CA047559, CA04326, U10 CA180882, CA47559, CA45418, U10CA180821, CA31946, U10 CA003927  
Corr. Author:
 
Authors:
                     
Networks:
LAPS-IL057, LAPS-MN026, LAPS-NC010, LAPS-TX035, NC002, NC012   
Study
CALGB-10301
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Multiple myeloma, proteasome inhibitors, anthracyclines, international staging system